ArticleFrontiers in cellular and infection microbiology2025
Ellagic acid mitigates rotavirus-induced intestinal injury via bidirectional "immune-microbiota" regulatory effect.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dietary Ellagic Acid Protects and Ameliorates Copper Sulfate-Induced Toxicity in Common Carp (Veterinary sciences · 2026Article
- Curcumol alleviates cardiac and cerebral injury caused by encephalomyocarditis virus (EMCV) in Kunming mice via suppressing NF-κB/NLRP3 inflammasome pathway.Frontiers in pharmacology · 2026Article
- Natural products against Babesiosis: active compounds, molecular mechanisms, application limitations and translational development.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rotavirus (RV) is a major cause of childhood gastroenteritis, leading to intestinal damage, inflammation, and gut microbiota dysbiosis. This study investigated whether ellagic acid (EA), a natural polyphenol, can alleviate RV-induced intestinal injury by modulating both host immunity and the gut microbiota. Methods: In this study, RV was used to infect BALB/c suckling mouse models to explore whether ellagic acid could alleviate intestinal damage following rotavirus infection through bidirectional regulation of "immunity and microbiota". The viral load of RV, the expression levels of IL-1β, IL-6, and TNF-α mRNA were detected by qPCR. The pathological changes in the jejunal tissue were observed by hematoxylin and eosin (H&E) staining. The expression of JAM1, ZO-1, and Claudin-4 proteins in jejunal tissue were detected by immunohistochemistry (IHC). The expressions of TLR4, MYD88, IκBα, and P-P65 proteins in jejunal tissues were detected by WB. 16S rDNA gene sequencing was employed to detect the structural changes of the microbiota in feces, and qPCR was used to detect the colonization of Lactobacillus johnsonii, Lactobacillus reuteri, and Lactobacillus gasseri in jejunal tissues. Results: The qPCR results revealed that ellagic acid could significantly (P < 0.001) reduce the viral load as well as the mRNA expression levels of IL-1β, IL-6, and TNF-α in RV-infected BALB/c suckling mice. The results of H&E staining demonstrated that ellagic acid could alleviate villus rupture and vacuolation lesions induced by RV and significantly (P < 0.05) alleviate intestinal villus shortening and crypt deepening caused by RV. The IHC results showed that ellagic acid could significantly increase the expression of tight junction proteins JAM1, ZO-1, and Claudin-4 in RV-infected BALB/c neonatal mice. The WB results showed that ellagic acid significantly (P< 0.001) inhibited the expression of the TLR4/NF-κB signaling pathway. The results of 16S rDNA gene sequencing showed that ellagic acid could lead to a significant (P < 0.05) increase in the abundance of intestinal Lactobacillus bacteria ( Discussion: Ellagic acid can alleviate intestinal damage following rotavirus infection through bidirectional regulation of "immunity and microbiota", providing a theoretical foundation and innovative concepts for the research and development of EA as an anti-RV drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.